Why Do Some Doctors Prescribe Longer Antibiotic Treatment for Lyme Disease?
Treatment duration varies in clinical practice
Persistent symptoms remain difficult to evaluate
Guidelines differ on retreatment decisions
Many respondents who reported a prior Lyme disease diagnosis also reported antibiotic treatment extending beyond four weeks.
Hook and colleagues found that among respondents who reported having been diagnosed with Lyme disease, 39.0% reported antibiotic treatment for 4 weeks or less, 20.3% reported treatment for 5 to 8 weeks, and 35.6% reported treatment for more than 8 weeks.
“A surprisingly large proportion of respondents reported receiving more than 8 weeks of antibiotic treatment for LD,” Hook and colleagues wrote in Ticks and Tick-borne Diseases.
What did the survey actually show?
The Hook survey does not show that extended antibiotic treatment has become the “new norm.” It also does not prove whether longer treatment was appropriate or inappropriate for any individual patient.
The study relied on self-reported survey data. The authors could not verify the treatment duration, identify the antibiotic used, review patient charts, or determine why clinicians prescribed longer courses.
That distinction matters. A survey can document what patients report, but it cannot determine the clinical reasoning behind those treatment decisions.
Why might some doctors prescribe longer antibiotic treatment?
Some physicians may consider longer antibiotic treatment for Lyme disease when patients remain ill after initial therapy, have persistent or relapsing symptoms, present with neurologic involvement, have delayed diagnosis, or require reassessment for possible coinfections or other medical conditions.
Some clinicians follow shorter fixed-duration recommendations. Others use a more individualized approach, particularly when patients have not returned to baseline or have objective evidence of ongoing disease activity.
The key clinical question is not simply how long the prescription lasted. The more important question is whether the treatment decision was based on careful reassessment, risk-benefit discussion, and the patient’s clinical response.
Why do Lyme disease guidelines differ?
The CDC authors cited the familiar position that antibiotic treatment beyond standard guideline durations has not shown clear benefit in several controlled trials for patients with persistent symptoms after Lyme disease.
They also expressed concern about antibiotic-related complications and antimicrobial resistance.
However, the ILADS guidelines take a different approach. The ILADS panel concluded that the evidence base for many Lyme disease treatment questions is limited and that clinical judgment, patient preferences, severity of illness, treatment response, and risk of ongoing morbidity should be considered.
As an author of the ILADS guidelines, I believe treatment decisions should not be reduced to a rigid duration alone. Patients who remain ill require reassessment, not automatic dismissal.
Persistent symptoms after Lyme disease treatment
Persistent symptoms after Lyme disease treatment remain a major source of disagreement. Rebman and Aucott reviewed persistent symptoms in Lyme disease and noted that some patients report fatigue, cognitive difficulties, musculoskeletal pain, sleep disruption, paresthesias, headache, dizziness, and mood changes after treatment.
The cause of these persistent symptoms is not settled. Proposed mechanisms include microbial persistence, immune dysregulation, inflammatory or autoimmune pathways, altered neural networks, coinfections, repeat exposures, and overlapping medical conditions.
This uncertainty is one reason treatment decisions remain controversial. Some patients may need evaluation for alternative diagnoses, while others may need reassessment for persistent or relapsing tick-borne disease.
What do IDSA guidelines recommend?
The 2020 IDSA/AAN/ACR guidelines recommend defined antibiotic courses for specific Lyme disease presentations, including erythema migrans, neurologic Lyme disease, Lyme carditis, and Lyme arthritis.
These guidelines generally discourage additional antibiotic therapy for patients who have nonspecific persistent symptoms after recommended treatment when there is no objective evidence of active infection.
That approach differs from ILADS, which places more emphasis on individualized retreatment discussions for patients with persistent manifestations, especially when the illness remains functionally significant and other causes have been reconsidered.
Does longer treatment ever have evidence?
Some clinical manifestations of Lyme disease have been treated with longer courses than early erythema migrans. For example, Logigian and colleagues evaluated 30 days of intravenous ceftriaxone in patients with Lyme encephalopathy who met strict criteria.
In that uncontrolled case series, memory scores, CSF protein levels, and SPECT perfusion findings improved after treatment.
This does not mean every patient with persistent symptoms should receive intravenous antibiotics. It does show that treatment duration depends on the clinical syndrome, disease stage, objective findings, and patient response.
When should Lyme disease treatment be extended or changed?
The decision should not depend on symptoms alone or on a predetermined treatment duration. It requires reassessing the original diagnosis, illness severity, objective findings, treatment response, adverse effects, possible coinfections, and other conditions that could explain persistent symptoms.
Continue or extend treatment: Additional treatment may be considered when the patient remains significantly ill but has shown meaningful improvement, has persistent or recurrent objective findings, was diagnosed late, or may have received insufficient initial treatment. The potential benefit should remain greater than the risks.
Change treatment: A different antibiotic, route, or treatment strategy may be considered when improvement has stalled, medication is poorly tolerated, absorption or adherence is uncertain, the clinical manifestation requires another approach, or a coinfection is suspected.
Stop or reconsider: Treatment should be paused or stopped when serious adverse effects develop, risks exceed potential benefits, or therapy provides no meaningful benefit. Lack of improvement should also prompt evaluation for anemia, thyroid disease, sleep disorders, autoimmune illness, medication effects, autonomic dysfunction, structural problems, or another infection. It does not by itself prove either persistent infection or that Lyme disease was never present.
Frequently Asked Questions
Why do some doctors prescribe longer antibiotic treatment for Lyme disease?
Some doctors prescribe longer antibiotic treatment when patients remain ill, relapse, have delayed diagnosis, show neurologic or other complicated manifestations, or require individualized reassessment. The rationale should be based on clinical findings, treatment response, and risk-benefit discussion.
Did the Hook survey prove longer Lyme treatment is the new norm?
No. The Hook survey showed that many respondents reported receiving antibiotic treatment longer than 4 weeks, but it did not verify treatment details or determine why clinicians prescribed those courses.
Do all Lyme disease guidelines agree on treatment duration?
No. IDSA/AAN/ACR guidelines generally recommend defined treatment durations and discourage additional antibiotics for nonspecific persistent symptoms without objective evidence of active infection. ILADS guidelines emphasize individualized assessment and shared decision-making when patients remain ill.
Can Lyme symptoms persist after antibiotics?
Yes. Some patients report persistent fatigue, pain, cognitive symptoms, sleep disruption, paresthesias, dizziness, or mood changes after treatment. The causes may vary and require careful evaluation.
Does longer antibiotic treatment always help?
No. Longer antibiotic treatment does not help every patient and carries risks. The decision should depend on the diagnosis, disease manifestation, prior response, competing explanations, and patient-specific risk-benefit assessment.
How does a doctor decide whether to extend or change Lyme disease treatment?
The clinician should reassess the diagnosis, objective findings, treatment response, adverse effects, illness duration, possible coinfections, and alternative explanations. Improvement may support continued treatment, while toxicity, lack of benefit, or evidence of another condition may support changing or stopping it.
Clinical Takeaway
The Hook survey showed that many patients reported receiving antibiotic treatment for Lyme disease beyond 4 weeks, but it did not determine why those treatment decisions were made or whether they were clinically appropriate.
Patients who remain ill after Lyme disease treatment deserve individualized reassessment rather than treatment decisions based solely on antibiotic duration.
Related Articles
These related articles explore treatment response, persistent symptoms, recovery, and differing approaches to Lyme disease care.
Failure rates still too high for the treatment of Lyme disease
Over 20% of Lyme disease patients still remain ill after treatment
Post-treatment Lyme disease syndrome
Persistent Lyme disease mechanisms
Recovery from Lyme disease
References
- Hook SA, Nelson CA, Mead PS. U.S. public’s experience with ticks and tick-borne diseases: Results from national HealthStyles surveys. Ticks Tick Borne Dis. 2015;6(4):483-488.
- Cameron DJ, Johnson LB, Maloney EL. Evidence assessments and guideline recommendations in Lyme disease: the clinical management of known tick bites, erythema migrans rashes and persistent disease. Expert Rev Anti Infect Ther. 2014;12(9):1103-1135.
- Rebman AW, Aucott JN. Post-treatment Lyme Disease as a Model for Persistent Symptoms in Lyme Disease. Front Med (Lausanne). 2020;7:57.
- Lantos PM, Rumbaugh J, Bockenstedt LK, et al. Clinical Practice Guidelines by the Infectious Diseases Society of America, American Academy of Neurology, and American College of Rheumatology: 2020 Guidelines for the Prevention, Diagnosis and Treatment of Lyme Disease. Clin Infect Dis. 2021;72(1):1-8.
- Talbot NC, Spillers NJ, Luther P, et al. Lyme Disease and Post-treatment Lyme Disease Syndrome: Current and Developing Treatment Options. Cureus. 2023;15(8):e43112.
- Logigian EL, Kaplan RF, Steere AC. Successful treatment of Lyme encephalopathy with intravenous ceftriaxone. J Infect Dis. 1999;180(2):377-383.
Dr. Daniel Cameron, MD, MPH
Lyme disease clinician with over 30 years of experience and past president of ILADS.
Symptoms • Testing • Coinfections • Recovery • Pediatric • Prevention
The incorrect dogma comes from our ‘friends’ at the IDSA.
These guys are still clinging to their 2006 guidelines .. the guidelines they updated a while back reporting that old guidelines are what’s for dinner … I’m not sure why they are getting paid …
So, what is the more up to date time line of treatment these days? I have been on antibiotics for 4 months now and my PA is saying it could be as long as 18 months.
Kent
I find it difficult to predict how long the treatment will last. I have patients who are better much quicker than they imagined I have had to individualize treatment for my patients.